MSI-1701

MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

Analogues that differ from MSI-1436 at only a single stereocenter, such as MSI-1701 (the polyamine at C-3) or MSI-1777 (the methyl at C-20) exhibit significantly reduced activity, while MSI-1673 (the OH at C-7) is completely inactive[1].

Experiments are performed using age-matched (4 to 5 weeks old) male mice provided food and water ad lib. Mice corresponding to a single experimental cohort are housed together in a single cage. Animals are used 1 week after arrival. Drug dosing is conducted with 10 mg/kg of each compound (including MSI-1701) via the i.p. route every 3 days for 4 doses, beginning on day 0[1].

[1]. Michael Zasloff, et al. Therapeutic uses for aminosterol compounds. US 7410959 B1.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline